SENORES PHARMACEUTICALS L (SENORES) - Net Assets
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) has net assets worth Rs8.34 Billion INR (≈ $90.24 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs12.88 Billion ≈ $139.31 Million USD) and total liabilities (Rs4.54 Billion ≈ $49.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SENORES PHARMACEUTICALS L tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs8.34 Billion |
| % of Total Assets | 64.78% |
| Annual Growth Rate | -36.21% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 215.46 |
SENORES PHARMACEUTICALS L - Net Assets Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's net assets have evolved over time, based on quarterly financial data. See SENORES PHARMACEUTICALS L (SENORES) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for SENORES PHARMACEUTICALS L (2022–2025)
The table below shows the annual net assets of SENORES PHARMACEUTICALS L from 2022 to 2025. For live valuation and market cap data, see SENORES company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs94.96 Million ≈ $1.03 Million |
-95.90% |
| 2024-03-31 | Rs2.32 Billion ≈ $25.06 Million |
+409.26% |
| 2023-03-31 | Rs454.99 Million ≈ $4.92 Million |
+24.35% |
| 2022-03-31 | Rs365.90 Million ≈ $3.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SENORES PHARMACEUTICALS L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5251.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs899.10 Million | 11.44% |
| Common Stock | Rs460.50 Million | 5.86% |
| Other Components | Rs6.50 Billion | 82.71% |
| Total Equity | Rs7.86 Billion | 100.00% |
SENORES PHARMACEUTICALS L Competitors by Market Cap
The table below lists competitors of SENORES PHARMACEUTICALS L ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Province Commun
SHG:603018
|
$655.40 Million |
|
Memsensing Microsystems Suzhou China Co Ltd
SHG:688286
|
$655.44 Million |
|
Harson Trading China Co Ltd
SHG:603958
|
$655.47 Million |
|
Aura Biosciences Inc
NASDAQ:AURA
|
$655.47 Million |
|
Jiangsu SINOJIT Wind Energy Technology Co Ltd
SHG:601218
|
$655.12 Million |
|
Wolong Real Estate Group Co Ltd
SHG:600173
|
$655.01 Million |
|
MTY Food Group Inc
TO:MTY
|
$654.98 Million |
|
NTG Nordic Transport Group A/S
CO:NTG
|
$654.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SENORES PHARMACEUTICALS L's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,042,680,000 to 7,861,900,000, a change of 5,819,220,000 (284.9%).
- Net income of 6,846,015 contributed positively to equity growth.
- New share issuances of 4,717,600,000 increased equity.
- Other factors increased equity by 1,094,773,985.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs6.85 Million | +0.09% |
| Share Issuances | Rs4.72 Billion | +60.01% |
| Other Changes | Rs1.09 Billion | +13.93% |
| Total Change | Rs- | 284.88% |
Book Value vs Market Value Analysis
This analysis compares SENORES PHARMACEUTICALS L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 165.56x to 6.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | Rs7.95 | Rs1315.40 | x |
| 2023-03-31 | Rs9.88 | Rs1315.40 | x |
| 2024-03-31 | Rs44.35 | Rs1315.40 | x |
| 2025-03-31 | Rs216.18 | Rs1315.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SENORES PHARMACEUTICALS L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.18%
- • Asset Turnover: 26.28x
- • Equity Multiplier: 0.02x
- Recent ROE (0.09%) is below the historical average (9.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 2.71% | 7.04% | 0.24x | 1.62x | Rs-26.68 Million |
| 2023 | 18.53% | 23.87% | 0.27x | 2.88x | Rs38.83 Million |
| 2024 | 15.40% | 14.92% | 0.34x | 3.04x | Rs110.23 Million |
| 2025 | 0.09% | 0.18% | 26.28x | 0.02x | Rs-779.34 Million |
Industry Comparison
This section compares SENORES PHARMACEUTICALS L's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $12,455,102,985
- Average return on equity (ROE) among peers: 28.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SENORES PHARMACEUTICALS L (SENORES) | Rs8.34 Billion | 2.71% | 0.54x | $655.14 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $20.07 Billion | 16.78% | 0.50x | $4.15 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $3.29 Billion | 14.62% | 0.66x | $203.47 Million |
| Pfizer Limited (PFIZER) | $42.03 Billion | 17.19% | 0.17x | $2.25 Billion |
| Sanofi India Limited (SANOFI) | $6.08 Billion | 27.83% | 0.41x | $839.48 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $1.23 Billion |
| TTK Healthcare Limited (TTKHLTCARE) | $1.18 Billion | 13.66% | 1.33x | $134.99 Million |
About SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more